鲁抗医药2025年净利同比预降逾六成

Core Viewpoint - Lu Kang Pharmaceutical (600789) expects a significant decrease in net profit for 2025, projecting a range of 110 million to 145 million yuan, representing a year-on-year decline of 63.26% to 72.13% [1] Financial Performance - The anticipated decrease in profit is primarily attributed to the impact of non-recurring gains and losses, market factors, and short-term cost pressures related to strategic investments [1] - The previous year's performance was boosted by substantial asset disposal gains from the completion of land transfer procedures, leading to significant fluctuations in this year's results [1] Industry Context - The pharmaceutical industry is facing overall profit pressure due to slowing product market demand, intense competition, and price reductions from national centralized procurement policies [1] - Traditional human formulation products are experiencing significant changes in terminal demand, leading to pressures on volume and pricing adjustments, which have negatively impacted revenue and gross profit [1] Strategic Investments - To promote high-quality development, the company is increasing its investment in research and development, focusing on innovative drugs, high-end formulations, and synthetic biology [1] - The increase in amortization expenses related to previously approved technical assets and the sustained high level of R&D investment are expected to have a short-term negative impact on profits [1]